New 2021 Diagnosis and Procedure Codes Related to COVID-19

[Pages:2]January 22, 2021 Web Announcement 2414

New 2021 Diagnosis and Procedure Codes Related to COVID-19

Effective with dates of service on or after January 1, 2021, six new 2021 International Classification of Diseases, Tenth Revision, Clinical Modification (ICD-10-CM) Novel Coronavirus (COVID-19) diagnosis codes and 21 new International Classification of Diseases, Tenth Revision, Procedure Coding System (ICD-10-PCS) COVID-19 procedure codes have been added to the Medicaid Management Information System (MMIS) for billing.

The six ICD-10-CM diagnosis codes implemented by the Centers for Disease Control and Prevention's (CDC) National Center for Health Statistics (NCHS) are:

Diagnosis Code J12.82 M35.81 M35.89 Z11.52 Z20.822 Z86.16

Code Description Pneumonia due to coronavirus disease 2019 Multisystem inflammatory syndrome Other specified systemic involvement of connective tissue Encounter for screening for COVID-19 Contact with and (suspected) exposure to COVID-19 Personal history of COVID-19

The 21 ICD-10-PCS procedure codes implemented by the Centers for Medicare & Medicaid Services (CMS) are:

Procedure Code XW013H6 XW013K6 XW012S6 XW012T6 XW013U6 XW023S6 XW023T6 XW023U6 XW033E6 XW033F6

Code Description

Introduction of Other New Technology Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6

Introduction of Leronlimab Monoclonal Antibody into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6

Introduction of COVID-19 Vaccine Dose 1 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6

Introduction of COVID-19 Vaccine Dose 2 into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6

Introduction of COVID-19 Vaccine into Subcutaneous Tissue, Percutaneous Approach, New Technology Group 6

Introduction of COVID-19 Vaccine Dose 1 into Muscle, Percutaneous Approach, New Technology Group 6

Introduction of COVID-19 Vaccine Dose 2 into Muscle, Percutaneous Approach, New Technology Group 6

Introduction of COVID-19 Vaccine into Muscle, Percutaneous Approach, New Technology Group 6

Introduction of Etesevimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6

Introduction of Bamlanivimab Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6

Web Announcement 2414

January 22, 2021

Page 1 of 2

Procedure Code XW033G6 XW033H6 XW033L6 XW043E6 XW043F6 XW043G6 XW043H6 XW043L6 XW0DXM6 XW0G7M6 XW0H7M6

Code Description

Introduction of REGN-COV2 Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6

Introduction of Other New Technology Monoclonal Antibody into Peripheral Vein, Percutaneous Approach, New Technology Group 6

Introduction of CD24Fc Immunomodulator into Peripheral Vein, Percutaneous Approach, New Technology Group 6

Introduction of Etesevimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6

Introduction of Bamlanivimab Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6

Introduction of REGN-COV2 Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6

Introduction of Other New Technology Monoclonal Antibody into Central Vein, Percutaneous Approach, New Technology Group 6

Introduction of CD24Fc Immunomodulator into Central Vein, Percutaneous Approach, New Technology Group 6

Introduction of Baricitinib into Mouth and Pharynx, External Approach, New Technology Group 6

Introduction of Baricitinib into Upper GI, Via Natural or Artificial Opening, New Technology Group 6

Introduction of Baricitinib into Lower GI, Via Natural or Artificial Opening, New Technology Group 6

Web Announcement 2414

January 22, 2021

Page 2 of 2

 ................
................

In order to avoid copyright disputes, this page is only a partial summary.

Google Online Preview   Download